Table 3. SMR and AER for all-cause late... | American Society of Hematology

Table 3.

SMR and AER for all-cause late mortality among 2-year survivors of autologous BMT in childhood

Variable	Entire cohort,	Number of all-cause deaths				Rate of all-cause death per 1000 person-years
Variable	no. of patients	Observed	Expected	SMR	95% CI	Observed	Expected	AER	95% CI
All patients	345	103	4.7	21.8	17.9-26.3	20.4	0.9	19.4	15.5-23.4
Sex
Male	212	53	3.9	13.8	10.4-17.8	15.7	1.1	14.6	10.4-18.8
Female	133	50	0.9	57.9	43.3-75.4	29.6	0.5	29.0	20.9-37.2
Age at BMT, y
0-4	97	28	0.8	36.4	24.5-51.6	19.6	0.5	19.1	11.8-26.3
5-9	57	20	0.7	29.2	18.2-43.9	20.9	0.7	20.2	11.0-29.3
10-14	55	19	0.7	26.2	16.1-39.7	24.7	0.9	23.8	12.7-34.9
15-21	136	36	2.5	14.2	10.1-19.4	18.9	1.3	17.6	11.4-23.7
Year of BMT
<1990	74	33	1.8	18.2	12.7-25.2	22.8	1.3	21.5	13.8-29.3
1990-1999	129	37	1.9	19.7	14.2-26.8	16.8	0.9	15.9	10.5-21.3
2000-2010	142	33	1.0	32.0	22.3-44.2	23.5	0.7	22.7	14.7-30.7
Source of stem cells
Bone marrow	163	53	3.1	17.0	14.1-24.6	17.4	1.0	16.4	11.7-21.4
PBSCs	181	50	1.6	31.6	22.0-39.9	25.0	0.8	24.2	17.3-31.1
Primary diagnosis
ALL	43	21	0.9	24.0	15.2-35.8	26.8	1.1	25.7	14.2-37.2
AML	45	6	0.9	6.8	2.7-13.8	6.5	1.0	5.5	0.3-10.7
HL	90	23	1.5	15.2	9.8-22.2	18.9	1.3	17.7	9.9-25.4
NHL	31	8	0.6	13.0	6.0-24.3	15.9	1.2	14.7	3.7-25.7
Neuroblastoma	79	25	0.5	52.6	24.6-76.0	24.2	0.5	23.8	14.3-33.3
Other malignant disease*	57	20	0.4	56.4	35.1-84.8	33.2	0.6	32.6	18.1-47.2
Disease status at HCT
Standard risk of relapse†	133	39	2.5	15.4	11.1-20.8	17.1	1.1	16.0	10.6-21.4
High risk of relapse	212	64	2.2	29.2	22.6-37.0	23.0	0.8	22.2	16.6-27.9
Overall survival after HCT, y
2-5	65	65	0.1	660.8	512.9-834.7	319.5	0.5	319.0	241.3-396.7
6-9	73	24	0.3	78.4	51.1-114.1	41.9	0.5	41.4	24.6-58.1
10-14	45	9	0.4	20.6	9.9-37.2	15.9	0.8	15.2	4.8-25.5
15+	162	5	3.9	1.3	0.5-2.8	1.3	1.0	0.3	−0.9-1.5

Variable	Entire cohort,	Number of all-cause deaths				Rate of all-cause death per 1000 person-years
Variable	no. of patients	Observed	Expected	SMR	95% CI	Observed	Expected	AER	95% CI
All patients	345	103	4.7	21.8	17.9-26.3	20.4	0.9	19.4	15.5-23.4
Sex
Male	212	53	3.9	13.8	10.4-17.8	15.7	1.1	14.6	10.4-18.8
Female	133	50	0.9	57.9	43.3-75.4	29.6	0.5	29.0	20.9-37.2
Age at BMT, y
0-4	97	28	0.8	36.4	24.5-51.6	19.6	0.5	19.1	11.8-26.3
5-9	57	20	0.7	29.2	18.2-43.9	20.9	0.7	20.2	11.0-29.3
10-14	55	19	0.7	26.2	16.1-39.7	24.7	0.9	23.8	12.7-34.9
15-21	136	36	2.5	14.2	10.1-19.4	18.9	1.3	17.6	11.4-23.7
Year of BMT
<1990	74	33	1.8	18.2	12.7-25.2	22.8	1.3	21.5	13.8-29.3
1990-1999	129	37	1.9	19.7	14.2-26.8	16.8	0.9	15.9	10.5-21.3
2000-2010	142	33	1.0	32.0	22.3-44.2	23.5	0.7	22.7	14.7-30.7
Source of stem cells
Bone marrow	163	53	3.1	17.0	14.1-24.6	17.4	1.0	16.4	11.7-21.4
PBSCs	181	50	1.6	31.6	22.0-39.9	25.0	0.8	24.2	17.3-31.1
Primary diagnosis
ALL	43	21	0.9	24.0	15.2-35.8	26.8	1.1	25.7	14.2-37.2
AML	45	6	0.9	6.8	2.7-13.8	6.5	1.0	5.5	0.3-10.7
HL	90	23	1.5	15.2	9.8-22.2	18.9	1.3	17.7	9.9-25.4
NHL	31	8	0.6	13.0	6.0-24.3	15.9	1.2	14.7	3.7-25.7
Neuroblastoma	79	25	0.5	52.6	24.6-76.0	24.2	0.5	23.8	14.3-33.3
Other malignant disease*	57	20	0.4	56.4	35.1-84.8	33.2	0.6	32.6	18.1-47.2
Disease status at HCT
Standard risk of relapse†	133	39	2.5	15.4	11.1-20.8	17.1	1.1	16.0	10.6-21.4
High risk of relapse	212	64	2.2	29.2	22.6-37.0	23.0	0.8	22.2	16.6-27.9
Overall survival after HCT, y
2-5	65	65	0.1	660.8	512.9-834.7	319.5	0.5	319.0	241.3-396.7
6-9	73	24	0.3	78.4	51.1-114.1	41.9	0.5	41.4	24.6-58.1
10-14	45	9	0.4	20.6	9.9-37.2	15.9	0.8	15.2	4.8-25.5
15+	162	5	3.9	1.3	0.5-2.8	1.3	1.0	0.3	−0.9-1.5

Includes 25 Ewing sarcomas, 11 Wilms tumor, 9 CNS tumors, 4 desmoplastic small round cell tumors, 6 soft tissue sarcoma, 1 ovarian tumor, 1 hepatoblastoma, and 1 multiple myeloma.

†

Standard risk: first or second complete remission after acute leukemia or lymphoma; all others high risk.

View Large

This Feature Is Available To Subscribers Only